BenevolentAI

AI Healthcare Tools AI Research & Education Tools

↳AI Medical Research & Clinical Decision Support

Custom

Clinical-stage AI drug discovery with integrated wet labs and AstraZeneca and Merck collaborations

Not yet rated

Released 2013

Visit Website

Gallery

4 items

VIDEO

About BenevolentAI

BenevolentAI (Euronext Amsterdam: AMS: BAI) is a leading clinical-stage AI drug discovery and development company founded in London in 2013. With $1.9B in total capital raised and a business model that uniquely combines AI-powered target identification with in-house wet lab validation, BenevolentAI operates at the frontier of both computational and experimental drug discovery — making it a fully integrated AI biotech rather than a pure software platform.

At the heart of BenevolentAI is the Benevolent Platform — a proprietary AI system that builds a dynamic knowledge graph from scientific literature, biomedical databases, genomic data, and experimental findings. The platform uses machine learning to uncover hidden relationships between genes, proteins, diseases, and drugs, surfacing novel therapeutic targets and disease hypotheses that escape human detection. These AI-generated insights are then validated in BenevolentAI's own Cambridge wet labs, closing the loop between AI prediction and biological reality. Strategic collaborations with AstraZeneca and Merck provide additional external validation of the platform's target identification capabilities.

BenevolentAI is best suited for pharmaceutical companies seeking to expand their target identification pipelines through AI-powered knowledge mining, researchers working on complex diseases with limited therapeutic options (ulcerative colitis, glioblastoma, ALS, fibrosis, Parkinson's), and institutional investors seeking exposure to a differentiated, publicly traded AI biotech on the European markets.

Key Features

Benevolent Platform — AI knowledge graph integrating scientific literature, databases, and experimental data
Target identification and disease hypothesis generation from multimodal biomedical data
In-house wet lab facilities in Cambridge UK for AI hypothesis validation
Clinical pipeline: BEN-8744 (Phase 1, ulcerative colitis), BEN-28010 (preclinical, glioblastoma), BEN-34712 (preclinical, ALS)
Strategic collaborations with AstraZeneca and Merck for AI-powered drug target discovery
Knowledge exploration tools for pharma partners — licensed separately from drug pipeline
Integrated AI + wet lab model: AI generates hypotheses, scientists validate in physical experiments
Multi-disease focus: oncology, rare disease, fibrosis, CNS, immunology, and cardiovascular
Listed on Euronext Amsterdam (AMS: BAI) — $1.9B total raised since founding in 2013
Offices in London HQ, Cambridge wet labs, and New York

Pros

Fully integrated AI + wet lab model — unique among AI drug discovery platforms
AstraZeneca and Merck partnerships validate the platform's target identification quality
In-house wet labs in Cambridge close the loop between AI prediction and biology
Euronext Amsterdam listed (AMS: BAI) — $1.9B raised, publicly accountable
Phase 1 clinical data for BEN-8744 (ulcerative colitis) represents real clinical progress
Multiple disease areas covered: oncology, rare disease, CNS, fibrosis, and immunology
Knowledge exploration tools can be licensed separately from drug pipeline

Cons

Listed on Euronext Amsterdam (AMS: BAI) — less accessible to US retail investors
Clinical pipeline still in early stages — no approved drugs yet
Smaller than competitors like Recursion in terms of funding and team size
Revenue dependent on collaboration milestones — lumpy and uncertain
Wet-lab operations add cost complexity vs. pure software drug discovery peers

Pricing

BenevolentAI operates through enterprise pharma collaboration agreements and platform licensing — there is no self-serve access or published pricing.

Revenue models include: discovery collaborations with pharma companies (AstraZeneca, Merck) structured as multi-year agreements with upfront fees and milestones; licensing of its knowledge exploration tools as standalone software to pharma R&D organizations; and advancing its own clinical pipeline to inflection points for licensing or co-development.

Total funding raised is approximately $1.9B, with the company listed on Euronext Amsterdam (AMS: BAI). Contact BenevolentAI through benevolent.com for partnership and platform licensing inquiries.

Claim Verified Creator Badge

Are you the founder of BenevolentAI? Display this listing's verified badge on your website to show your customers that your product has been vetted and listed on AI Central Resources.

HTML Embed Code

<a href="https://www.aicentralresources.com/tool/benevolentai" target="_blank" rel="noopener">
  <img src="https://www.aicentralresources.com/badges/featured-badge-dark.svg" alt="Featured on AICentralResources" width="200" height="54" style="border: none;" />
</a>

* Place this HTML snippet in your website's footer, landing page, or press section. This creates a search-friendly backlink directly to your verification page.

Connect with BenevolentAI

X (Twitter)LinkedIn

Frequently Asked Questions

The Benevolent Platform is BenevolentAI's proprietary AI system that integrates scientific literature, biomedical databases, and experimental data to build a knowledge graph. It uses AI to uncover hidden relationships between genes, proteins, diseases, and drugs — surfacing novel drug targets and disease hypotheses that human scientists would miss.

BenevolentAI has strategic collaborations with AstraZeneca (multi-target AI drug discovery) and Merck (complex disease biology). These partnerships validate its platform's ability to identify novel targets and generate drug candidates for conditions including chronic kidney disease, cancer, and rare diseases.

BenevolentAI's pipeline includes BEN-8744 (PDE10 inhibitor in Phase 1 for ulcerative colitis), BEN-28010 (CHK1 inhibitor in preclinical for glioblastoma), BEN-34712 (preclinical for ALS), and candidates for fibrosis and Parkinson’s disease.

BenevolentAI (AMS: BAI) is listed on Euronext Amsterdam. It went public through a SPAC merger in April 2022 at a $1.61B valuation. Total funding raised stands at approximately $1.9B.

BenevolentAI combines AI with in-house wet-lab validation — unlike pure software platforms, it physically validates AI-generated drug hypotheses in its Cambridge wet labs. It also takes drugs through its own clinical pipeline rather than purely licensing technology, making it a fully integrated AI drug development company.